Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06952660 · ClinicalTrials.gov registry record · Phase 4

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

A Phase 4 study of Cervical Cancer, sponsored by Pfizer.

Recruiting
Registry status
Phase 4
Development phase
100
Enrollment target
20
Study locations

NCT06952660 is a Phase 4 study of Cervical Cancer that is actively recruiting participants, run by Pfizer. The registered enrollment target is 100 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06952660, a Phase 4 study of Cervical Cancer, is actively recruiting participants, sponsored by Pfizer.

RECRUITING
Registry status
Phase 4
Development phase
100 participants
Enrollment target
20
Study locations

Study Summary

TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possible side effects of TIVDAK, specially to any side effect that is related to the eye. A side effect is anything a medicine does to your body that is not part of how the medicine treats disease. * This study is seeking for participants who: Are willing to take all the required eye tests * Have not received TIVDAK before * Do not have any active eye issues. Participants will receive TIVDAK once every 3 weeks as an infusion that will be injected into the vein. Participants will visit an eye care provider at 3 stages: * before starting the treatment, * before each of the first 9 infusions * then monthly for 3 months after they stop taking TIVDAK. Treatment with TIVDAK will continue until it is not working anymore against the participant's cancer.

Conditions Studied

Cervical Cancer

Interventions

  • DRUG TIVDAK

Study Locations (20)

Florida

  • Mount Sinai Comprehensive Cancer Center - Aventura - Aventura
  • Florida Cancer Specialists - Bonita Springs
  • Florida Cancer Specialists - Bradenton
  • Florida Cancer Specialists - Cape Coral
  • Broward Health Coral Springs - Coral Springs
  • Florida Cancer Specialists - Daytona Beach
  • Broward Health North - Deerfield Beach
  • Florida Cancer Specialists - Fleming Island
  • Broward Health Imperial Point - Fort Lauderdale
  • Broward Health Medical Center - Fort Lauderdale
  • Florida Cancer Specialists - Fort Myers
  • Florida Cancer Specialists - Fort Myers
  • HCA Mercy Hospital - Miami
  • Mount Sinai Comprehensive Cancer Center - Miami Beach
  • Mount Sinai Medical Center of Florida, Inc - Miami Beach
  • Florida Cancer Specialists - N. Venice
  • Florida Cancer Specialists - Naples
  • Orlando Health Cancer Institute - Orlando
  • Orlando Health Orlando Regional Medical Center - Orlando
  • Orlando Health Winnie Palmer Hospital for Women & Babies - Orlando

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-05-07
Est. Completion 2028-12-13
Phase Phase 4

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06952660

The ClinicalTrials.gov registry entry for NCT06952660 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which TIVDAK is the first listed.

NCT06952660 reports 20 study locations spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06952660 about?

NCT06952660 is a clinical study titled "Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer". TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possib...

What is the current status of trial NCT06952660?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2025-05-07. Estimated completion is 2028-12-13.

What conditions does trial NCT06952660 study?

This clinical trial studies the following conditions: Cervical Cancer.

What interventions are being tested in trial NCT06952660?

The interventions under investigation include: TIVDAK (DRUG).

Who is sponsoring clinical trial NCT06952660?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06952660 being conducted?

This trial has 20 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cervical Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cervical Cancer

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.